Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 4, 2007

MacroChem to Pay Upwards of $42M for Rights to Genaera’s Anti-Infective

  • MacroChem has exercised the option it acquired in July to develop Genaera’s late-stage anti-infective for mild diabetic foot infection. Macrochem will make an initial payment of $1 million through February 1, 2008 and could provide over $42 million in milestone fees.

    Macrochem thus gains the exclusive, worldwide license to Genaera’s small peptide drug, pexiganan. “We believe this is a unique opportunity for MacroChem to broaden its product portfolio with a product that has already completed two Phase III trials,” states Robert J. DeLuccia, president and CEO of MacroChem. He also points out that the product complements the company’s lead candidate, EcoNail®, for treatment of nail fungus.

    Under the terms of the agreement, Genaera will receive $7 million upon the achievement of certain clinical and regulatory goals. The company is also entitlted to sales-based milestones of up to $35 million and 10% royalty payments on net sales. MacroChem will assume all clinical development, manufacturing, and regulatory activities for pexiganan.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »